^
Association details:
Biomarker:BRCA2 mutation
Cancer:Ovarian Cancer
Drug:bemcentinib (BGB324) (AXL inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

Effect of inhibition of receptor tyrosine kinase AXL by a selective small molecular inhibitor R428 (BGB321) on DNA damage repair response in ovarian cancer cells.

Published date:
05/28/2020
Excerpt:
AXL inhibitor R428 sensitized both BRCA mutated and non-BRCA-mutated OC cells to a potent and highly selective ATR inhibitor.
DOI:
10.1200/JCO.2020.38.15_suppl.e15640